The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia.
The formation of the unique fusion gene, bcr-abl, and the resultant increase in abl tyrosine kinase activity, is seen as the major driving force in the initiation of chronic myelogenous leukaemia (CML). The deregulation of abl tyrosine kinase activity, brought about by the binding of a portion of the Scr molecule to the SH2 regulatory domain of abl, appears to play a role in promoting resistance to drug-induced apoptosis. Thus the large increase In mature myeloid cells seen in CML could be the direct result of the suppression of apoptosis by the bcr-abl fusion protein. The role and contribution of apoptosis in the progression of CML and the possible role of antisense oligonucleotides to the bcr-abl gene as therapeutic agents is discussed.
Fernandes
R S
RS
Tumour Biology Laboratory, Department of Biochemistry, University College Cork, Ireland.
Gorman
A M
AM
McGahon
A
A
Lawlor
M
M
McCann
S
S
Cotter
T G
TG
D017209:Apoptosis / Q000235:genetics*; D016044:Fusion Proteins, bcr-abl / Q000502:physiology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*
D016376:Oligonucleotides, Antisense; D016044:Fusion Proteins, bcr-abl